Cathepsin K inhibitors as treatment of bone metastasis

Current Opinion in Supportive and Palliative Care

Volumn 2, Issue 3, 2008, Pages 218-222

  Gall, Celine Le ^a,b   Bonnelye, Edith ^a,b   Clézardin, Philippe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Bone metastasis; Breast cancer; Cathepsin K; Osteoclast; Prostate cancer

Indexed keywords

AZEPINE DERIVATIVE; BALICATIB; BENZAMIDE DERIVATIVE; BIPHENYL DERIVATIVE; CATHEPSIN; CATHEPSIN K; N (1 (((CYANOMETHYL)AMINO)CARBONYL)CYCLOHEXYL) 4 (2 (4 METHYLPIPERAZIN 1 YL) 1,3 THIAZOL 4 YL)BENZAMIDE; N-(1-(((CYANOMETHYL)AMINO)CARBONYL)CYCLOHEXYL)-4-(2-(4-METHYLPIPERAZIN-1-YL)-1,3-THIAZOL-4-YL)BENZAMIDE; ODANACATIB; PIPERAZINE DERIVATIVE; RELACATIB; SULFONE; THIAZOLE DERIVATIVE;

BONE REMODELING; BONE TUMOR; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; METABOLISM; METASTASIS; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; PROSTATE TUMOR; REVIEW;

AZEPINES; BENZAMIDES; BIPHENYL COMPOUNDS; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; BREAST NEOPLASMS; CATHEPSINS; FEMALE; HUMANS; MALE; OSTEOCLASTS; PIPERAZINES; PROSTATIC NEOPLASMS; SULFONES; THIAZOLES;

EID: 54049123792     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32830baea9     Document Type: Article

References (27)

1. Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implica tions. Clin Exp Metastasis 2007; 24:599-608.
2. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6:764-775.
3. Vasiljeva O, Reinheckel T, Peters C, et al. Emerging roles of cysteine cathepsins in disease and heir potential as drug targets. Curr Pharm Design 2007; 13:385-401.
4. Asagiri M, Hirai T, Kunigami T, etal. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008; 319:624-627.
5. Funicello M, Novelli M, Ragni M, et al. Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores. PLoS One 2007; 2:e683.
6. Yang M, Zhang Y, Pan J, et al. Cathepsin L activity controls adipogenesis and glucose tolerance. Nat Cell Biol 2007; 9:970-977.
7. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273:1236-1238.
8. Saftig P, Hunziker E, Wehmeyer O, etal. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998; 95:13453-13458.
9. Kiviranta R, Morko J, Uusitalo H, et al. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Min Res 2001;16:1444-1452.
10. Everts V, Korper W, Hoeben KA, etal. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Min Res 2006; 21:1399-1408.
11. Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997; 57:5386-5390.
12. Brubaker KD, Vessella RL, True LD, et al. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Min Res 2003; 18:222-230.
13. Le Gall C, Bellahcène A, Bonnelye E, et al. A cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden. Cancer Res 2007; 67:9894-9902.
14. Bellahcène A, Bachelier R, Detry C, et al. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 2007; 101:135-148.
15. Quintanilla-Dieck MJ, Codriansky K, Keady M, etal. Cathepsin K in melanoma cell invasion. J Invest Dermatol 2008 [Epub ahead of print].
16. GrabowskaUB,ChambersTJ, ShirooM.Recentdevelopmentsin cathepsinK inhibitor design. Curr Opin Drug Discov Dev 2005; 8:619-630.
17. Stoch SA, WagnerJA. Cathepsin Kinhibitors: anovel targetforosteoporosis therapy. Clin Pharmacol Ther 2008; 83:172-176.
18. Gauthier JY, Chauret N, Cromlish W, etal. The discovery of odanacatib (MK- 0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008; 18:923-928.
19. Xiang A, Kanematsu M, Kumar S, et al. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in variectomized mice. Bone 2007; 40:1231-1237.
20. Fuller K, Lawrence KM, Ross JL, et al. Cathepsin K inhibitors prevent matrix- derived growth factor degradation by human osteoclasts. Bone 2008; 42:200-211.
21. DesmaraisS,BlackWC,OballaR,etal.EffectofcathepsinKinhibitorbasicity on /n v/vo off-target activities. Mol Pharmacol 2008; 73:145-156. Provides evidence that cathepsin K inhibitors severely impair the activity of other cysteine cathepsins.
22. Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor ofcathepsin K (relacatib) reduces biomarkers of bone resorption both in vivo and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007;40:122-131.
23. Wesolowski G, Pickarski M, Neusch G, et al. Inhibition of osteolytic bone metastasesinbreastcancerwithcathepsinKinhibitor. JBoneMinRes2007;22 (Suppl 1):S112; abstract.
24. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440:692-696.
25. Dewar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antire- sorptive therapy for bone disease. Blood 2006; 107:4334-4337.
26. Hamdy NA. Denosumab: RANKL inhibition in the management ofbone loss. Drugs Today2008; 44:7-21.
27. Kim SJ, Uehara H, Yazici S, et al. Modulation ofbone microenvironment with zoledronateenhancesthetherapeuticeffectsofSTI571 andpaclitaxelagainst experimental bone metastasis ofhuman prostate cancer. Cancer Res 2005;65:3707-3715.